Dermatology

Cotton gloves showed superior comfort and practicability among patients with hand dermatoses.

Despite this, investigators noted that patients with ICI-induced bullous pemphigoids experienced relatively improved tumor responses.

The study suggested that dermatologists in academic settings were more likely to utilize teledermatology prior to the limitations of the COVID-19 pandemic as well.

New phase 3 data found that 70% of patients with atopic dermatitis achieved EASI-75 following treatment with lebrikizumab and topical corticosteroids

A new systematic review found that patients with the dermatologic condition experienced moderate impairment of health-related quality of life and emotions.

Conversely, age was shown to have a negative association, as did the highest category of physical activity.

Botulin toxin was first approved by the FDA in 2002 for cosmetic reasons.

Differences in rosacea subtypes were also observed regarding patient sex, continent of origin, and the year of publication.

In data presented at AAD, investigators found increased odds of GERD in patients with rosacea compared to a control group without rosacea.

The investigative team also observed a significant association between psoriasis, IBS, anxiety, and depression in patients with diabetes and rosacea.

Among the different rosacea phenotypes included in the study, no statistical difference in ANAs was observed.

The highest epidermal thickness was calculated for Asian skin at the forehead while the lowest epidermal thickness was for African skin at the dorsal forearm.

Significantly higher incidence rates of alopecia areata were seen in Hispanic children.

In recent years, researchers and advocates have vocalized increasing psychological support for patients with psoriasis.

A new AAD study shows board-certified experts produce only one-fourth of the most popular TikTok posts on subjects in their field.

An assessment of long-term VOYAGER 1 and 2 trial data show the IL-23 biologic provides significant benefit toward skin clearance, regardless of baseline characteristics.

The VALIANT study featured a cross-sectional online survey that was used to recruit adult patients 18 years and older who were professionally diagnosed with vitiligo.

Data from the ADhere studies found that lebrikizumab was well tolerated in patients with atopic dermatitis.

A pair of novel topical drugs hit high phase 3 marks at AAD 2022. One expert explains how they both may reach ground-breaking indications.

Clinical responses including PASI 100 and absolute PASI, and PASI ≤2 were maintained through week 96 with the biologic in patients with psoriasis, with no new safety signals identified.

New AAD 2022 data support the novel gel therapy as the potentially first treatment for the viral-borne skin condition.

The new oral medicine helped some patients with mild to moderate psoriasis achieve and sustain PASI-50 after the initial study period.

Amy S. Paller, MD, concludes her AAD 2022 interview with a look into the future of pediatric systemic therapy—and a call to assure due diligence in tracking patient progression among her peers.

Dedee F. Murrell, MD, details the EASE trial findings presented at AAD 2022, and what the benefit of the novel topical gel may mean for patients with EB.

A new AAD 2022 study shows disparities in patch testing for allergens—and how certain fragrances, metals and preservations discriminately affect rates of contact dermatitis.